Biote (BTMD) Q1 2026: Recall Drives $1.7M Revenue Hit, Sales Force Expansion Sets Up H2 Rebound
Biote’s Q1 was defined by a voluntary recall that cut into revenue and margins, but the company accelerated sales force hiring and continued practitioner onboarding, laying groundwork for a second-half recovery. Management held full-year guidance, citing pent-up demand and restored supply as tailwinds for H2, while dietary supplements remained a bright spot. Investors should watch the pace of inventory normalization and the impact of expanded commercial capacity as leading indicators for revenue reacceleration.
Summary
- Supply Disruption Overshadows Operations: Recall-driven inventory constraints weighed on core procedure revenue and gross margin.
- Commercial Buildout Accelerates: Sales team expansion and record practitioner training support future growth trajectory.
- Second-Half Recovery in Focus: Leadership expects pent-up demand and supply normalization to drive H2 rebound.
Business Overview
Biote (BTMD) is a provider of bioidentical hormone therapy and wellness solutions, primarily targeting practitioners in the hormone optimization and healthy aging markets. The company generates revenue from procedure kits, hormone pellet sales, and dietary supplements, with its two core segments being procedure revenue (from hormone therapy procedures performed by practitioners) and dietary supplement sales (primarily via e-commerce and clinics). Biote’s business model is built on expanding its network of trained practitioners and supporting them with ongoing product and service offerings.
Performance Analysis
Q1 results were materially impacted by a voluntary recall of certain hormone pellet inventory, resulting in a $1.7M revenue shortfall and $1.5M in incremental recall costs. Procedure revenue, the company’s largest segment, declined as both existing clinic volumes and new clinic productivity were hampered by supply constraints and sales force distraction. Dietary supplement revenue, however, grew double digits, propelled by e-commerce channel strength and partially offsetting weakness in the core procedure business.
Gross margin compressed due to higher costs associated with the recall and an increased reliance on third-party suppliers, as internal production at Asteria Health, Biote’s vertically integrated manufacturing arm, was temporarily reduced. Operating expenses rose, reflecting both higher legal costs and investments in commercial infrastructure. Despite these headwinds, Biote generated positive cash flow and repaid its remaining share repurchase liabilities, maintaining a healthy liquidity position.
- Recall-Driven Margin Compression: Gross margin fell as recall costs and third-party supply diluted profitability.
- Dietary Supplements Outperform: This segment delivered robust growth, highlighting the value of channel diversification.
- Sales Force Expansion Completed: Over 25 new hires in Q1 bring total sales personnel to 120, positioning Biote for accelerated practitioner onboarding in coming quarters.
While Q1 performance fell short of expectations, leading indicators such as practitioner training sessions and commercial team buildout suggest a return to growth is plausible once supply stabilizes and pent-up demand is addressed.
Executive Commentary
"We have strengthened our commercial organization, expanded our sales team, and enhanced our capabilities to better support practitioners and their patients... While the impacts are expected to continue into the second quarter, we believe this is a temporary issue, and it does not affect our long-term strategy or alter the overall demand environment."
Brett Christensen, Chief Executive Officer
"Our goal remains to meet customer needs through the vertical integration of Asteria Health... We anticipate fully restoring Asteria Health's supply continuity by the end of the second quarter."
Bob Peterson, Chief Financial Officer
Strategic Positioning
1. Recall Response and Supply Chain Resilience
The voluntary recall exposed vulnerability in Biote’s supply chain but also triggered rapid operational adjustments. The company leveraged third-party suppliers and added a second shift at Asteria Health to rebuild inventory and restore safety stock, aiming to return to full internal production and margin normalization by late Q2.
2. Commercial Team Expansion
Biote accelerated its sales force buildout, hiring over 25 new reps in Q1 to reach a target of 120. This investment is designed to drive practitioner network growth and improve account service, with new hires expected to contribute meaningfully once supply constraints ease and focus returns to acquisition and retention.
3. Practitioner Pipeline and Training
Practitioner training sessions hit near-full capacity, with a 16.5% YoY increase in new practitioners trained. This onboarding pipeline is a leading indicator for future procedure and supplement revenue, as it typically takes six months for new practitioners to ramp up to meaningful contribution.
4. Segment Diversification and Channel Resilience
Dietary supplement revenue growth, especially via e-commerce, demonstrated the importance of segment and channel diversification in offsetting core procedure volatility. Management continues to forecast mid to high single-digit growth in supplements for 2026.
5. Focus on Top-Tier Clinics and Retention
Biote is sharpening its focus on maximizing value from its top clinics, introducing measures to improve retention and lifetime value, and refining its practitioner recruitment to target higher-value specialties such as OBGYN and general practitioners.
Key Considerations
This quarter’s results underscore both the risks of supply concentration and the benefits of a diversified commercial strategy. The recall was a stress test for Biote’s operational resilience and highlighted the strategic necessity of vertical integration and third-party partnerships.
Key Considerations:
- Supply Chain Recovery Pace: Timely normalization of Asteria Health inventory is critical for margin and revenue restoration.
- Sales Force Productivity: The ability of the expanded sales team to drive practitioner growth will be tested as supply constraints ease.
- Practitioner Retention and Ramp: Sustained engagement and onboarding of high-value practitioners are essential for procedure revenue rebound.
- Dietary Supplement Momentum: Continued outperformance in supplements could partially buffer core segment risk if volatility persists.
Risks
Biote remains exposed to supply chain disruptions, particularly if Asteria Health’s inventory normalization takes longer than expected or if third-party partners face their own constraints. Competitive pressures in hormone therapy and practitioner attrition, while stable, could rise if service levels falter. Regulatory risk remains inherent in the compounding and distribution of hormone therapies, and margin recovery depends on a smooth transition back to internal production.
Forward Outlook
For Q2 2026, Biote expects:
- Continued but diminishing impact from the recall on procedure revenue and gross margin.
- Progressive normalization of inventory by late Q2, supporting a return to regular practitioner servicing and new business development.
For full-year 2026, management maintained guidance:
- Revenue above $190 million.
- Adjusted EBITDA greater than $38 million.
Management highlighted several factors that underpin confidence in H2 recovery:
- Pent-up demand from delayed procedures and patient rescheduling.
- Expanded sales force and robust practitioner training pipeline expected to unlock growth as supply stabilizes.
Takeaways
Biote’s Q1 was a reset quarter marked by external disruption but also by proactive investment in future growth levers.
- Recall Impact Was Material but Temporary: Supply constraints drove revenue and margin shortfalls, but management expects normalization within weeks, supported by production ramp and third-party sourcing.
- Commercial Investments Set the Stage for Growth: Expanded sales capacity and strong practitioner onboarding are positioned to drive a second-half rebound as operational distractions wane.
- Watch Inventory and Practitioner Ramp: Investors should monitor the pace of inventory normalization and the productivity of new sales hires as leading indicators for revenue inflection in H2 2026.
Conclusion
While Q1 performance was hampered by an unexpected recall, Biote’s response—bolstering supply chain resilience and accelerating commercial investments—suggests the business is positioning for a return to growth in the second half. The next several quarters will be a test of execution as the company seeks to convert expanded capacity and practitioner engagement into sustained revenue momentum.
Industry Read-Through
Biote’s experience this quarter offers a cautionary tale for specialty healthcare providers reliant on vertically integrated manufacturing. Supply disruptions can rapidly cascade through both revenue and practitioner engagement, underscoring the need for diversified sourcing and robust contingency planning. The strong performance of dietary supplements and e-commerce channels highlights the value of segment diversification in healthcare, especially when core procedure volumes are volatile. Other hormone therapy and wellness companies should heed the operational and commercial lessons from Biote’s recall response, particularly the importance of practitioner pipeline health and rapid sales force mobilization in mitigating temporary setbacks.